Posted by Michael Wonder on 11 Jun 2021
Incyte announces U.S. FDA has extended the new drug application review period for ruxolitinib cream for the treatment of atopic dermatitis
11 June 2021 - Incyte announced today that the U.S. FDA has extended the review period for the new drug application for ruxolitinib cream for the treatment of atopic dermatitis.
The Prescription Drug User Fee Act action date has been extended by three months to 21 September 2021.
